Trial Profile
A Phase II Study of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Dexamethasone
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 20 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Apr 2019 Planned End Date changed from 1 Jan 2023 to 1 Jul 2021.
- 29 Apr 2019 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2021.